LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Accueil・Liste d'Actions・Catalent Inc

Search

Catalent Inc

Fermé

Secteur Soins de santé

60.01 -0.41

Résumé

Variation du prix de l'action

24h

Actuel

Min

59.93

Max

60.3

Chiffres clés
By Trading Economics
Revenu	124M 23M
Ventes	180M 1.3B
P/E Moyenne du Secteur	28.82 112.16
BPA	0.65
Marge bénéficiaire	1.769
EBITDA	83M 105M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	+5.34 upside

Dividendes
By Dow Jones
Prochains Résultats	13 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	3.6M 11B
Ouverture précédente	60.42
Clôture précédente	60.01

Sentiment de l'Actualité

By Acuity

50%

50%

171 / 366 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

60.09 / 60.6099 Support & Résistance

Catalent Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 mai 2024, 13:51 UTC

Acquisitions, Fusions, Rachats

FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal

5 févr. 2024, 14:50 UTC

Acquisitions, Fusions, Rachats

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 4th Update

5 févr. 2024, 13:11 UTC

Acquisitions, Fusions, Rachats

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 3rd Update

5 févr. 2024, 12:09 UTC

Acquisitions, Fusions, Rachats

Novo Holdings to Buy Catalent in $16.5 Billion Deal -- 2nd Update

5 févr. 2024, 11:38 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Buys Manufacturing Sites as Part of Novo Holdings' Acquisition of Catalent

5 févr. 2024, 11:31 UTC

Acquisitions, Fusions, Rachats

Novo Holdings Buying Catalent in $16.5 Billion Deal -- Update

5 févr. 2024, 11:23 UTC

Acquisitions, Fusions, Rachats

Novo Holdings Buying Catalent in $16.5 Billion Deal

23 mars 2024, 13:00 UTC

Actualités

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street -- WSJ

5 févr. 2024, 18:04 UTC

Acquisitions, Fusions, Rachats

Wegovy Maker to Boost Production Capacity With Multibillion-Dollar Deal -- WSJ

5 févr. 2024, 17:27 UTC

Résultats

Acquisitions, Fusions, Rachats

Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming. -- Barrons.com

5 févr. 2024, 15:36 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk To Up Production Capacity As Parent Buys Catalent -- IBD

5 févr. 2024, 11:38 UTC

Acquisitions, Fusions, Rachats

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk -- Barrons.com

5 févr. 2024, 11:15 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk's Controlling Shareholder To Buy Catalent For $16.5 Billion -- MarketWatch

5 févr. 2024, 11:08 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk: Manufacturing Sites Are in Italy, Belgium and US

5 févr. 2024, 11:08 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Buys Sites From Novo Holdings as Part of Novo Holdings' Deal to Buy Catalent

5 févr. 2024, 11:06 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Agrees to Buy Three Manufacturing Sites For Upfront Payment of $11 Bln

5 févr. 2024, 11:03 UTC

Acquisitions, Fusions, Rachats

Catalent: Merger Is Expected to Close Towards the End of Calendar Yr 2024 >CTLT

5 févr. 2024, 11:02 UTC

Acquisitions, Fusions, Rachats

Catalent: Of Co's More Than 50 Global Sites, Novo Holdings Intends to Sell Three Catalent Fill-Finish Sites and Related Assets Acquired in Merger to Novo Nordisk >CTLT

Comparaison

Variation de prix

Catalent Inc prévision

Objectif de Prix

By TipRanks

5.34% hausse

Prévisions sur 12 Mois

Moyen 63.5 USD 5.34%

Haut 63.5 USD

Bas 63.5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

0

Achat

1

Maintien

0

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

60.09 / 60.6099Support & Résistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

171 / 366Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Catalent Inc

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

Autres valeurs du secteur

LLY

Eli Lilly and Co.

916.07

UNH

UnitedHealth Group Inc

566.13

NVO

Novo Nordisk A-S

118.17

JNJ

Johnson and Johnson

164.55

ABBV

AbbVie Inc

188.57